Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are distinct in pathobiological characteristics. Asthma is a disease with its origins in child hood, is related to allergies and eosinophils, and is best treated by targeting inflammation, whereas COPD is related to adults who smoke and to neutrophils, and is best treated with bronchodilators and the removal of risk factors. However, this distinction is not always clear-cut and there is a considerable overlap in pathogenesis and clinical features; patients with severe asthma may present with fixed airway obstruction while patients with COPD may have hyperresponsiveness and eosinophilia (Kim & Rhee, 2010) . In fact, the classification of patients having asthma or COPD may vary day-to-day based on established diagnostic criteria, due to their overlap and inherent variability in bronchodilator responsiveness (Calverley et al., 2003) . Moreover, several hypotheses/theories have been proposed to explain whether they are in a single disease entity.
In accord with this concept for the two diseases, recent diagnostic approaches appear to be concentrated on various and specific phenotypes because of their different therapeutic responses to the standard treatment for each disorder depending on the phenotypes. The refractory asthmatic patients share several characteristics of patients with COPD, suggesting that drugs in discovery for COPD might also be effective in treating severe asthma (Barnes, Mar 2008 , Dec 2008 . In fact, many new drugs under pre-or clinical trials are expected to be effective in both diseases and overlapping situations. However, there remains still a need to extend novel drug development and to investigate the mechanisms and treatment of overlapping asthma and COPD. In this chapter, we will review these special therapeutic considerations for severe or refractory entity, i.e., overlap of two major airway obstructive disorders, asthma and COPD. be recognized as distinct disease entities. Actually, asthma has been differentiated from pure COPD through several condition described as follows; i) youthful onset, ii) non-smokers, iii) episodic and completely reversible airway obstruction and airway hyperresponsiveness, and iv) allergic history including the association with rhinitis. In addition, a dysregulated T helper cell (Th) type 2 inflammatory response is responsible for the eosinophilic and mononuclear cell infiltration, mucous metaplasia, airway remodeling are seen in asthma patients and characterize asthma. However, each disorder has a very wide spectrum of clinical and pathobiological phenotypes thereby in considerable patients the diagnosis becomes vague, confusing, and being overlapped (Kim & Rhee, 2010) . Thus, the current classification of obstructive airway diseases is not adequate to precisely treat COPD and asthma. Recently, different statistical techniques have been used to better understand and describe the multiple dimensions of airway diseases with the ultimate goal being identification of distinct subgroups of patients with different prognosis or response to treatment (Shirtcliffe et al., 2011) .
Asthma and COPD are representative chronic inflammatory lung diseases. In both conditions, inflammation is associated with episodic exacerbation and/or structural alteration at large and small airway levels (Guerra, 2005; Jeffery, 2004) . These can result in a transient phenotypic overlap or a combined syndrome with characteristics of both diseases.
Exacerbation of asthma and COPD is a clinically significant event and frequently associated with a decline in lung function and symptomatic aggravation (Gibson & Simpson, 2009 ). During exacerbation, airway inflammation becomes more exaggerated than in the mild and stable disease states, thereby the inflammation pattern changes (Mauad & Dolhnikoff, 2008) . Neutrophil recruitment is a prominent feature of acute exacerbation of chronic asthma (Lamblin et al., 1998) , probably owing to respiratory tract infection by viruses (Fahy et al., 1995; Wark et al., 2002) . Furthermore, neutrophilic inflammation in the absence of eosinophils is largely present in sudden-onset fatal asthma, and neutrophil numbers are highly elevated in status asthmaticus (Lamblin et al., 1998; Tsokos & Paulsen, 2002) . Thus, severe and fatal asthma may be mediated by neutrophils, which is quite different from the classical Th2-driven eosinophilic form. In COPD patients, an allergic profile of inflammation can occur, particularly during exacerbation. Airway eosinophilia is observed in chronic bronchitic patients with exacerbation and is associated with the upregulation of RANTES in the airway epithelium (Saet et al., 1994; Zhu et al., 2001 ). These observations indicate that inflammatory characteristics of asthma and COPD are interchangeable during exacerbation and infection.
The cytokine profile is also affected by disease severity. During exacerbation, Th1/Th2 patterns are reversed to some degree in each disease. Several studies have demonstrated that the level of IL-17 is elevated in asthma and COPD and is correlated with the presence of neutrophils and the decrease of lung function (Bullens et al., 2006; Matsunaga et al., 2006; Molet et al., 2001; Wong et al., 2001) . The elevation of IL-17 level is associated with increased neutrophilic inflammation during severe asthma or acute exacerbation (Wong et al., 2001) . In COPD, the role of IL-17 remains unclear, although the importance of IL-17 in stimulating chemokine production and the involvement of neutrophils and macrophages in promoting COPD pathogenesis suggest a potential connection (Curtis et al., 2007) . 
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Disease exacerbation in both asthma and COPD can lead to an accelerated decline in lung function (Stein et al., 1999; Stern et al., 2007) . Previous reports have shown an association between severe asthma exacerbation and an accelerated decline in forced expiratory volume in 1 s (FEV1), to a degree similar to that seen in patients with smoking and COPD (Vonk et al., 2003) . Another important observation is that the decline in FEV1 seen in patients with infrequent exacerbation is similar to that in a population without asthma. These findings suggest that repetitive episodes of exacerbation may result in fixed airflow obstruction in asthma and contribute to the phenotypic overlap between asthma and COPD.
Decreased distensibility and increased collapsibility of small airways including alveoli are prominent in asthmatic emphysema, whereas loss of elastic recoil is an important factor in the dynamic collapse of the airway in COPD (James & Wenzel, 2007) . Currently, there are at least two major pathophysiological mechanisms responsible for the development of emphysema: protease-antiprotease imbalance and apoptosis of structural cells (Spurzem & Rennard, 2005) . Increased elastin degradation and enhanced expression of proteases have been documented in asthma patients (Bousquet et al., 1996; James & Wenzel, 2007) . In IL-13-overexpressing transgenic mice, emphysema and the increased expression of a variety of matrix metalloproteinases (MMPs) and cathepsins have been observed (Zheng et al., 2000) . Intervention that neutralize MMPs or cathepsins has been shown to dramatically ameliorate IL-13-induced emphysematous responses. These findings suggest that IL-13 has the ability to induce alveolar remodeling responses in asthmatics. Moreover, in human asthma patients, the numbers of eosinophils, CD4 + T-cells, and macrophages are increased in alveolar tissue at the time symptoms appeared (Kraft et al., 1996 (Kraft et al., , 1999 . Furthermore, the degree of eosinophilic inflammation correlates positively with lung volume in asthma patients (Sutherland et al., 2004) . These data indicate that destruction of distal airways is a consequence of a chronic, long-lasting injury, which affects lung function in both COPD and asthma.
In addition, in COPD, there is evidence for remodeling, fibrosis, and inflammation in epithelium, reticular basement membrane, airway smooth muscles (ASM), and mucous glands, albeit with patterns different from those seen in asthmatics (Bosken et al., 1990; Nagai et al., 1985; Wright et al., 1983) . Furthermore, bronchodilator reversibility and AHR may be present in a significant proportion of COPD patients (Kerstjens et al., 1993) . Poorer pulmonary function is associated with a greater magnitude of AHR, and increasing severity of airway hyperresponsiveness is associated with faster rates of decline in lung function in continuing smokers (Tashkin et al., 1996) .
Taken together, both states of transient overlapping with exacerbation and permanent/chronic structural changes between asthma and COPD may exhibit severe phenotype and respond poorly to standard treatment for each disease.
Need for new therapeutic concept for overlap between asthma and COPD
There is now sufficient evidence to suggest that both asthma and COPD are complex heterogeneous disorders including overlapped features each other with distinct risk factors, pathophysiological processes, natural history, and treatment responses. However, current treatment guidelines for COPD and asthma are based on randomized trials of highly selected subgroups of patients, especially the very typical phenotypic group, i.e., Th2-predominant asthma and pure COPD (Shirtcliffe et al., 2011) . Therefore, the major unmet needs of current therapies include better treatment of severe and refractory disease entities such as overlap between asthma and COPD. In addition, considering the poor and different responses to current therapy in patients with overlap, the ultimate goal of treatment targeted to this group can be achieved when the interrelationship between overlapping situation and its cellular and molecular basis is understood. In fact, there are enormous efforts to find the pharmacological therapeutic ways to control these specific phenotypic conditions worldwide.
New therapeutic approaches for overlap between asthma and COPD

Bronchodilators
Bronchodilators are an important component for pharmacologic approaches preventing and relieving bronchoconstriction. Recent popular bronchodilators are  2 -agonists with long action duration (long acting  2 -agonist, LABA) such as salmeterol and formoterol, which last for over 12 hours. There are now several even longer-acting  2 -agonists (ultra-LABA) in development, including indacaterol, carmoterol, GW-642444, and BI-1744, which have a duration of action >24 hours and are suitable for once daily use (Cazzola & Matera, 2009) . A once daily muscarinic antagonist, tiotropium bromide, is less effective as a bronchodilator in asthma than the  2 -agonists and is used predominantly in COPD, but might be a useful addon therapy in some patients with severe asthma (H.W. Park et al., 2009) . Several new classes of bronchodilators including other once daily muscarinic antagonists are also in development. However, there are lots of challenges and hurdles to overcome bronchodilators' weaknesses as a single therapeutic agent.
Novel corticosteroids
Inhaled corticosteroids (ICS) are the most effective anti-inflammatory therapy for asthma and COPD. In addition, in case of asthma, corticosteroids are used as fixed combination inhalers, i.e., LABA plus corticosteroid, and to date, this combination therapy is known to be the most effective available therapy based on their synergistic effects. However, all currently available ICS are absorbed from the lung and thus have the potential for systemic side effect. This has led to a concerted effort to find safer ICS, with reduced oral bioavailability, reduced absorption from the lung or inactivation in the circulation. Moreover, airway inflammation in COPD responds poorly to corticosteroid administration (Barnes & Stockley, 2005; Culpitt et al., 1999; Keatings et al., 1997) , presumably because it is associated with neutrophils, CD8+T lymphocytes, and CD68+ macrophages, cells that are minimally inhibited by corticosteroids. Since asthma exacerbation exhibits mixed inflammatory pattern of asthma and COPD, in the case of overlap between asthma and COPD, the therapeutic efficacy of current corticosteroid to asthma is attenuated. To achieve disease modification, reductions in the frequency and severity of acute exacerbations and effective suppression of asthmatic and COPD-type airway inflammation, new corticosteroids and/or anti-inflammatory strategies are required. Actually, dissociated steroids designed to separate the side effect mechanisms from the anti-inflammatory mechanisms are expected to have a greater effect on enhancement of transcription for anti-inflammatory genes, and thus might have a better therapeutic efficacy with the reduction of side effects (Schaecke et al., 2004) . On the other hand, nonsteroidal selective glucocorticoid receptor activators (SEGRA), such as AL-438 and ZK-216438, are in development, although the effect of these drugs may not be efficacious as pre-existing corticosteroids.
Modulation of cytokines; IL-17
Several cytokines act as important players in pathogenesis of asthma and COPD (Barnes, 2008) . As for asthma, Th2 cytokines have been thought to play a major role in its pathobiology traditionally. Inhibition of Th2 cytokine, IL-4 is proven to be disappointing, but there is a continuing interest in blocking IL-13, a related cytokine that regulates IgE formation, particularly in severe asthma. In fact, several IL-13 and IL-4R blocking antibodies are now in clinical trials but to date, clinical studies in severe asthma have also been disappointing (Chiba et al., 2009; Wenzel et al., 2007) . Therefore, recent therapeutic approach for asthma and COPD is deviated to develop the drugs for these severe and mixed phenotypic groups. As one of hopeful candidates, mepolizumab is shown to reduce exacerbation in a particular subset of patients who have persistent sputum eosinophilia (Haldar et al., 2009; Nair et al., 2009 ).
IL-17, the cytokine being studied most actively nowadays, has attracted interest as a target in severe asthma as it might be a mediator of neutrophilic inflammation in severe asthma (James & Wenzel, 2007) . Given the role of IL-17 in the regulation of growth factors that promote granulopoiesis and production of chemokines that are involved in recruitment neutrophils, IL-17 plays a pivotal role in the neutrophil responses in the lung. In addition to severe asthma, steroid-resistant asthma may also feature a neutrophil-dependent component (Louis & Djukanovic, 2006) . In fact, neutrophils are largely steroid insensitive, and corticosteroids inhibit neutrophil apoptosis (Cox, 1995; Schleimer et al., 1989) , perhaps explaining the increase in neutrophilia in severe and steroid resistant asthmatics. Another key neutrophil protease, MMP-9, is a primary MMP enhanced in asthmatics, and the level of MMP-9 correlates with asthma severity Wenzel et al., 2003) . Furthermore, IL-17 increases MMP-9 level via recruitment of neutrophils to the lung (Prause et al., 2004 ).
Yet, the role of IL-17 and Th17 cells in COPD remains largely speculative, although the importance of IL-17 in stimulating chemokine production and the role of neutrophils and macrophages in promoting COPD pathogenesis have led to great deal of interest on their interrelationship (Curtis, 2007) . In addition, another possible link derives from IL-17's ability to drive MMP-9 production, which may directly link to tissue destruction observed in COPD (Prause et al., 2004) .
Taken together, these observations suggest a role of neutrophils in mediating severe and steroid-resistant asthma (Foley & Hamid, 2007; Kamath et al., 2005; Louis & Djukanovic, 2006) , indicating the therapeutic potential of blockade of IL-17 for the control of severe and steroid resistant asthma such as overlap with COPD.
Regulation of lipid mediators
To date, the only mediator antagonists currently used in therapy for airway inflammatory disorders are anti-leukotrienes, which block cysteinyl leukotriene (cysLT) type 1-receptors. Although these drugs are much less effective than ICS, a recent study has revealed that cysLTs are implicated in sub-epithelial fibrosis, one of structural changes in airway remodeling, in asthmatic airways through the induction of IL-11 expression (Lee et al., 2007) . Several other drugs that inhibit receptors or synthesis of lipid mediators are currently in development. Among them, some novel 5'-LO and 5'-LO-activating protein (FLAP) inhibitors are more effective in patients with neutrophilic inflammation because they block the production of leukotriene (LT)B4. However, an LTB4 receptor (BLT1) antagonist had no effect in mild asthma (Evans et al., 1996) .
Phosphodiesterase (PDE) inhibitors; targeting PDE4
P D E 4 i n h i b i t o r s h a v e b e e n i n d e v e l o p m e n t f o r m a n y y e a r s . I n t e r e s t i n t h i s c l a s s o f compound arose in the 1980s when it became clear that methylxanthines such as theophylline, which had been widely used for its bronchodilator action since the 1930s, were difficult to use and could be dangerous because of its side effects. As a consequence, safer substitutes have been sought. At the same time, it was discovered that theophylline is an nonselective inhibitor of PDEs. There are multiple families of PDEs; one of these families, PDE4, is expressed in ASM and in immune and pro-inflammatory cells (Torphy, 1988 (Torphy, , 1990 (Torphy, , 1991 (Torphy, , 1998 . PDE4 inhibitors have a wide spectrum of anti-inflammatory effects, inhibiting T cells, eosinophils, mast cells, ASM cells, epithelial cells, and nerve cells, and are very effective in animal models of asthma (Chung, 2006) . In accordance with these findings, an oral PDE4 inhibitor, roflumilast, has an inhibitory effect on allergen-induced responses in asthma and also reduces symptoms of asthma and lung function, similar to low doses of ICS (Bousquet et al., 2006) . In addition to asthma, COPD is also the target airway disorder of PDE4 inhibitors with improving FEV1 and preventing the acute exacerbation (Calverley et al., 2007 (Calverley et al., , 2009 Rabe et al., 2005) . Therefore, PDE4 inhibitors are expected to use for treating COPD associated with asthma or patients at risk of transient overlapping situation such as acute exacerbation.
Adenosine receptor inhibitors
One inflammatory mediator common to both airway diseases is adenosine, making its receptor signaling pathway to be a therapeutic target for asthma and COPD. Adenosine levels have been shown to increase in patients with asthma and COPD and in animal models having features of chronic airway disease (Zhou et al., 2009) . Moreover, inhalation of adenosine induces bronchoconstriction in patients with asthma and COPD (Caruso et al, 2007) . A non-selective adenosine receptor antagonist, theophylline, improves lung function and symptoms in asthma and COPD (Caruso et al, 2007; Zhou et al., 2009 ). Furthermore, adenosine receptors are expressed on most, if not all, inflammatory and stromal cell types involved in the pathogenesis of asthma and COPD. Extracellular adenosine elicits its effects by interacting with four adenosine receptors: A1R, A2AR, A2BR, and A3R (Polosa & Blackburn, 2009 ). Adenosine receptor signaling systems are complex, displaying different and specific actions in various inflammatory responses. Studies with animal models of airway disease have suggested that A1, A3, and A2B antagonists may be useful for the treatment of asthma and COPD, although their therapeutic efficacy remains to be fully evaluated. Various selective adenosine receptor antagonists are under preclinical or clinical studies with patients of asthma and/or COPD.
Kinase inhibitors: Nuclear factor (NF)-B, mitogen-activated protein kinase (MAPK), and phosphoinositide-3 kinase (PI3K) signaling pathways
Generally, kinases are a pivotal component of biological actions in living things. In airway inflammation, a tremendous number of kinases are implicated and play critical roles. NF-B regulates expression of various inflammatory genes that are involved in airway diseases (Adcock et al., 2006) . Indeed, small molecule inhibitors of the key enzyme IKK2/IKKb (inhibitor of B kinase) block inflammation induced by NF-B activation and are now in preclinical test (Karin et al., 2004) . In addition, p38 MAPK activates similar inflammatory genes to NF-B, and is activated in cells from patients with severe asthma (Bhavsar et al., 2008) . Several small molecule inhibitors are now in clinical study for the treatment of inflammatory diseases (Cuenda & Rousseau, 2007) . Most of all, PI3K signaling is the most anticipated target of future drugs for asthma and COPD. In particular, the major focus of interest has been PI3K and  isoforms in respiratory disorders including asthma. PI3K is important for chemotactic responses, and selective inhibitors are in development, whereas PI3K activation results in reduced steroid responsiveness through reducing histone deacetylase (HDAC)2 activity, thus PI3K inhibitors could potentially reverse corticosteroid resistance in severe asthma . In addition, selective inhibition of the PI3K signaling pathway suppresses IL-17 expression through regulation of NF-B activity in asthma (Park et al, 2010) . These findings suggest that PI3K/ targeting agent can be a promising therapeutic tool for the treatment and prevention of severe asthma having COPD natures and acute exacerbation.
Targeting regulatory T cells
Regulatory T cells in patients with corticosteroid resistance produce less IL-10 but this can be restored with vitamin D3 supplementation in vitro (Xystrakis et al., 2006) . Additionally, in corticosteroid-resistant patients with asthma, intake of vitamin D3 enhances IL-10 secretion from regulatory T cells in response to dexamethasone (Xystrakis et al., 2006) . However, the therapeutic effects of vitamin D3 and its analogue 1a,25-vitamin D3 (calcitriol) on refractory or steroid resistant asthma remains unclear and need to test in large-scaled clinical trials.
Conclusion
Despite the distinct clinical phenotypic features of asthma and COPD, there is considerable overlap of symptoms and pathogenesis, and several hypotheses have been proposed regarding the status of asthma and COPD as a single disease entity. Overlapping features may occur not only in a permanent form but also as a transient symptom, as in exacerbation. In accordance with this, recent therapeutic approaches have concentrated on a target common to the pathogenesis of both asthma and COPD. Classic pharmacologic agents are innovating as new drugs to avoid significant side effects and to cover the patients at risk frequent exacerbation and refractory severe disease status in asthma and COPD. Novel candidate targets include various kinase pathways, adenosine receptors, lipid mediators, and PDE4, and almost of them are under preclinical or clinical trials. However, it still requires enormous efforts to develop novel classes of drugs overcoming the limitations of pre-existing medicines and to investigate the mechanisms and treatment of overlapping asthma and COPD.
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